Cargando…

Erratum: Correction of Acknowledgements Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update

Detalles Bibliográficos
Autores principales:	Wang, Sheng-Min, Han, Changsu, Lee, Soo-Jung, Jun, Tae-Youn, Patkar, Ashwin A, Masand, Prakash S, Pae, Chi-Un
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chonnam National University Medical School 2019
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351331/ https://www.ncbi.nlm.nih.gov/pubmed/30740348 http://dx.doi.org/10.4068/cmj.2019.55.1.73

Ejemplares similares

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Effectiveness and Tolerability of Switching to Aripiprazole Once Monthly from Antipsychotic Polypharmacy and/or Other Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2020)

Clinical Benefit and Utility of Switching to Aripiprazole Once Monthly in Patients with Antipsychotic Polypharmacy or Long Acting Injectable Antipsychotics for Patients with Schizophrenia in Routine Practice: A Retrospective, Observation Study
por: Pae, Chi-Un, et al.
Publicado: (2021)

Consideration of Long-Acting Injectable Antipsychotics for Polypharmacy Regimen in the Treatment of Schizophrenia: Put It on the Table or Not?
por: Pae, Chi-Un, et al.
Publicado: (2021)

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
por: Lee, Seung-Hoon, et al.
Publicado: (2022)

Vilazodone for the Treatment of Depression: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Exploring Hidden Issues in the Use of Antipsychotic Polypharmacy in the Treatment of Schizophrenia
por: Kim, Jung-Jin, et al.
Publicado: (2021)

Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
por: Wang, Sheng-Min, et al.
Publicado: (2015)

The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study
por: Han, Changsu, et al.
Publicado: (2019)

Additional Clinical Benefit of Agomelatine Treatment for Major Depressive Disorder in Naturalistic Treatment Setting
por: Lee, Kyung Ho, et al.
Publicado: (2023)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014)

Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for CACNA1C, CHRNA7 and MAPK1
por: Calabrò, Marco, et al.
Publicado: (2019)

Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample
por: Calabrò, Marco, et al.
Publicado: (2018)

Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder
por: Porcelli, Stefano, et al.
Publicado: (2014)

A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
por: Han, Changsu, et al.
Publicado: (2018)

Corrigendum: A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial
por: Han, Changsu, et al.
Publicado: (2020)

Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway
por: Cocchi, Enrico, et al.
Publicado: (2016)

Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
por: Wang, Sheng-Min, et al.
Publicado: (2018)

Investigating the effectiveness of a smart mental health intervention (inMind) for stress reduction during pharmacological treatment for mild to moderate major depressive disorders: Study protocol for a randomized control trial
por: Kim, Junhyung, et al.
Publicado: (2023)

Does Pregabalin Have Neuropsychotropic Effects?: A Short Perspective
por: Marks, David M., et al.
Publicado: (2009)

Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study
por: Lee, Seung-Hoon, et al.
Publicado: (2022)

Erratum: ACKNOWLEDGMENTS
Publicado: (2011)

The Influence of AHI1 Variants on the Diagnosis and Treatment Outcome in Schizophrenia
por: Porcelli, Stefano, et al.
Publicado: (2015)

Erratum: Acknowledgements Correction
Publicado: (2010)

Erratum: Acknowledgements Correction
Publicado: (2010)

Erratum: Funding Acknowledgment
por: Sohn, Cheongmin, et al.
Publicado: (2012)

Erratum: Funding Acknowledgment
por: Chung, Mi Ja, et al.
Publicado: (2012)

Erratum: Funding Acknowledgment
por: Jung, Ji-Hye, et al.
Publicado: (2012)

Erratum: Funding Acknowledgment
por: Baek, Jongmi, et al.
Publicado: (2013)

Erratum: Correction of Acknowledgements
por: Won, Se Yeon, et al.
Publicado: (2018)

Erratum: Correction of Acknowledgements
por: Park, Yu Ran, et al.
Publicado: (2018)

Erratum: Correction of Acknowledgements
por: Kim, Se Jeong, et al.
Publicado: (2018)

Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial
por: Shin, Cheolmin, et al.
Publicado: (2023)

Possible Modulatory Role of ARC Gene Variants in Mood Disorders
por: Crisafulli, Concetta, et al.
Publicado: (2021)

ZNF804A Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders
por: Calabrò, Marco, et al.
Publicado: (2020)

Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise
por: Marks, David M, et al.
Publicado: (2009)

Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice
por: Han, Changsu, et al.
Publicado: (2015)

Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder
por: Shin, Cheolmin, et al.
Publicado: (2021)

Epistatic Interactions between CREB and CREM Variants in Affective Disorder
por: Chiesa, Alberto, et al.
Publicado: (2014)

Triple Reuptake Inhibitors: The Next Generation of Antidepressants
por: Marks, David M, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_h5dar5rbo4hh9vknf97dque6pc